Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 12, 2021

SELL
$1.65 - $2.43 $302,169 - $445,013
-183,133 Closed
0 $0
Q3 2020

Oct 30, 2020

SELL
$1.6 - $2.35 $101,937 - $149,720
-63,711 Reduced 25.81%
183,133 $313,000
Q2 2020

Aug 05, 2020

SELL
$1.33 - $2.76 $26,214 - $54,399
-19,710 Reduced 7.39%
246,844 $573,000
Q1 2020

May 11, 2020

BUY
$0.97 - $2.85 $20,999 - $61,699
21,649 Added 8.84%
266,554 $413,000
Q4 2019

Feb 13, 2020

SELL
$1.69 - $3.8 $412,689 - $927,941
-244,195 Reduced 49.93%
244,905 $931,000
Q3 2019

Nov 08, 2019

BUY
$0.61 - $2.21 $298,351 - $1.08 Million
489,100 New
489,100 $900,000

Others Institutions Holding DRRX

About DURECT CORP


  • Ticker DRRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 227,794,000
  • Market Cap $194M
  • Description
  • DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...
More about DRRX
Track This Portfolio

Track Winton Group LTD Portfolio

Follow Winton Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Winton Group LTD with notifications on news.